Cargando…

Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection

We studied humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 152 long-term care facility staff and 124 residents over a prospective 4-month period shortly after the first wave of infection in England. We show that residents of long-term care facili...

Descripción completa

Detalles Bibliográficos
Autores principales: Tut, Gokhan, Lancaster, Tara, Butler, Megan S., Sylla, Panagiota, Spalkova, Eliska, Bone, David, Kaur, Nayandeep, Bentley, Christopher, Amin, Umayr, Jadir, Azar T., Hulme, Samuel, Ayodel, Morenike, Dowell, Alexander C., Pearce, Hayden, Zuo, Jianmin, Margielewska-Davies, Sandra, Verma, Kriti, Nicol, Samantha, Begum, Jusnara, Jinks, Elizabeth, Tut, Elif, Bruton, Rachel, Krutikov, Maria, Shrotri, Madhumita, Giddings, Rebecca, Azmi, Borscha, Fuller, Chris, Irwin-Singer, Aidan, Hayward, Andrew, Copas, Andrew, Shallcross, Laura, Moss, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154219/
https://www.ncbi.nlm.nih.gov/pubmed/37118449
http://dx.doi.org/10.1038/s43587-022-00224-w
_version_ 1785036079299035136
author Tut, Gokhan
Lancaster, Tara
Butler, Megan S.
Sylla, Panagiota
Spalkova, Eliska
Bone, David
Kaur, Nayandeep
Bentley, Christopher
Amin, Umayr
Jadir, Azar T.
Hulme, Samuel
Ayodel, Morenike
Dowell, Alexander C.
Pearce, Hayden
Zuo, Jianmin
Margielewska-Davies, Sandra
Verma, Kriti
Nicol, Samantha
Begum, Jusnara
Jinks, Elizabeth
Tut, Elif
Bruton, Rachel
Krutikov, Maria
Shrotri, Madhumita
Giddings, Rebecca
Azmi, Borscha
Fuller, Chris
Irwin-Singer, Aidan
Hayward, Andrew
Copas, Andrew
Shallcross, Laura
Moss, Paul
author_facet Tut, Gokhan
Lancaster, Tara
Butler, Megan S.
Sylla, Panagiota
Spalkova, Eliska
Bone, David
Kaur, Nayandeep
Bentley, Christopher
Amin, Umayr
Jadir, Azar T.
Hulme, Samuel
Ayodel, Morenike
Dowell, Alexander C.
Pearce, Hayden
Zuo, Jianmin
Margielewska-Davies, Sandra
Verma, Kriti
Nicol, Samantha
Begum, Jusnara
Jinks, Elizabeth
Tut, Elif
Bruton, Rachel
Krutikov, Maria
Shrotri, Madhumita
Giddings, Rebecca
Azmi, Borscha
Fuller, Chris
Irwin-Singer, Aidan
Hayward, Andrew
Copas, Andrew
Shallcross, Laura
Moss, Paul
author_sort Tut, Gokhan
collection PubMed
description We studied humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 152 long-term care facility staff and 124 residents over a prospective 4-month period shortly after the first wave of infection in England. We show that residents of long-term care facilities developed high and stable levels of antibodies against spike protein and receptor-binding domain. Nucleocapsid-specific responses were also elevated but waned over time. Antibodies showed stable and equivalent levels of functional inhibition against spike-angiotensin-converting enzyme 2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or other respiratory syncytial viruses. SARS-CoV-2-specific cellular responses were similar across all ages but virus-specific populations showed elevated levels of activation in older donors. Thus, survivors of SARS-CoV-2 infection show a robust and stable immunity against the virus that does not negatively impact responses to other seasonal viruses.
format Online
Article
Text
id pubmed-10154219
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-101542192023-05-04 Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection Tut, Gokhan Lancaster, Tara Butler, Megan S. Sylla, Panagiota Spalkova, Eliska Bone, David Kaur, Nayandeep Bentley, Christopher Amin, Umayr Jadir, Azar T. Hulme, Samuel Ayodel, Morenike Dowell, Alexander C. Pearce, Hayden Zuo, Jianmin Margielewska-Davies, Sandra Verma, Kriti Nicol, Samantha Begum, Jusnara Jinks, Elizabeth Tut, Elif Bruton, Rachel Krutikov, Maria Shrotri, Madhumita Giddings, Rebecca Azmi, Borscha Fuller, Chris Irwin-Singer, Aidan Hayward, Andrew Copas, Andrew Shallcross, Laura Moss, Paul Nat Aging Article We studied humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 152 long-term care facility staff and 124 residents over a prospective 4-month period shortly after the first wave of infection in England. We show that residents of long-term care facilities developed high and stable levels of antibodies against spike protein and receptor-binding domain. Nucleocapsid-specific responses were also elevated but waned over time. Antibodies showed stable and equivalent levels of functional inhibition against spike-angiotensin-converting enzyme 2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or other respiratory syncytial viruses. SARS-CoV-2-specific cellular responses were similar across all ages but virus-specific populations showed elevated levels of activation in older donors. Thus, survivors of SARS-CoV-2 infection show a robust and stable immunity against the virus that does not negatively impact responses to other seasonal viruses. Nature Publishing Group US 2022-05-30 2022 /pmc/articles/PMC10154219/ /pubmed/37118449 http://dx.doi.org/10.1038/s43587-022-00224-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Tut, Gokhan
Lancaster, Tara
Butler, Megan S.
Sylla, Panagiota
Spalkova, Eliska
Bone, David
Kaur, Nayandeep
Bentley, Christopher
Amin, Umayr
Jadir, Azar T.
Hulme, Samuel
Ayodel, Morenike
Dowell, Alexander C.
Pearce, Hayden
Zuo, Jianmin
Margielewska-Davies, Sandra
Verma, Kriti
Nicol, Samantha
Begum, Jusnara
Jinks, Elizabeth
Tut, Elif
Bruton, Rachel
Krutikov, Maria
Shrotri, Madhumita
Giddings, Rebecca
Azmi, Borscha
Fuller, Chris
Irwin-Singer, Aidan
Hayward, Andrew
Copas, Andrew
Shallcross, Laura
Moss, Paul
Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
title Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
title_full Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
title_fullStr Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
title_full_unstemmed Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
title_short Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
title_sort robust sars-cov-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154219/
https://www.ncbi.nlm.nih.gov/pubmed/37118449
http://dx.doi.org/10.1038/s43587-022-00224-w
work_keys_str_mv AT tutgokhan robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT lancastertara robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT butlermegans robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT syllapanagiota robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT spalkovaeliska robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT bonedavid robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT kaurnayandeep robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT bentleychristopher robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT aminumayr robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT jadirazart robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT hulmesamuel robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT ayodelmorenike robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT dowellalexanderc robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT pearcehayden robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT zuojianmin robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT margielewskadaviessandra robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT vermakriti robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT nicolsamantha robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT begumjusnara robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT jinkselizabeth robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT tutelif robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT brutonrachel robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT krutikovmaria robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT shrotrimadhumita robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT giddingsrebecca robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT azmiborscha robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT fullerchris robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT irwinsingeraidan robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT haywardandrew robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT copasandrew robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT shallcrosslaura robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection
AT mosspaul robustsarscov2specificandheterologousimmuneresponsesinvaccinenaiveresidentsoflongtermcarefacilitieswhosurvivenaturalinfection